Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Clinical Investigation

• Publication date

  1987-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI113223PMID 2960694PMCID PMC442401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177

  2004cited by this paper
• Quantitation of drug levels and platelet receptor blockade caused by a thromboxane antagonist

  1986cited by this paper
• Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548).

  1986cited by this paper
• Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.

  1986cited by this paper
• Measurement of renal and non-renal eicosanoid synthesis.

  1986cited by this paper
• The biochemical pharmacology of thromboxane synthase inhibition in man.

  1985influential reference
• Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.

  1985cited by this paper
• Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis.

  1985cited by this paper
• Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans.

  1985cited by this paper
• AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

  1985cited by this paper
• Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease.

  1984cited by this paper
• BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.

  1984cited by this paper
• PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER

  1984cited by this paper
• Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.

  1984cited by this paper
• Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells.

  1984cited by this paper
• Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy?

  1984cited by this paper
• Monitoring the entry of new platelets into the circulation after ingestion of aspirin.

  1983cited by this paper
• Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

  1983cited by this paper
• Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.

  1983cited by this paper
• Dipyridamole Inhibits Platelet Aggregation in Whole Blood

  1983cited by this paper
• Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

  1983cited by this paper
• Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

  1982cited by this paper
• Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.

  1982cited by this paper
• A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2.

  1982cited by this paper
• Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase.

  1981cited by this paper
• The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.

  1981cited by this paper
• Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.

  1981cited by this paper
• Thromboxane synthetase inhibition as antithrombotic strategy.

  1981cited by this paper
• INHIBITION OF THROMBOXANE SYNTHETASE DOES NOT NECESSARILY PREVENT PLATELET AGGREGATION

  1981cited by this paper
• The electronic aggregometer: a novel device for assessing platelet behavior in blood.

  1980cited by this paper
• Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells.

  1980cited by this paper
• Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.

  1980cited by this paper
• The use of immobilized ligands and [125I]protein a for immunoassays of thromboxane B2, prostaglandin D2, 13,14-dihydro-prostaglandin E2, 5,6-dihydro-prostaglandin I2, 6-keto-prostaglandin F1 alpha, 15-hydroxy-9 alpha, 11 alpha(epoxymethano)prosta-5,13-dienoic acid and 15-hydroxy-11 alpha,9 alpha(epo

  1979cited by this paper
• Regulation of blood platelet function by cyclic nucleotides.

  1978cited by this paper
• Reciprocal regulation of human platelet cAMP levels by thromboxane A2 and prostacyclin.

  1978cited by this paper
• Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma.

  1976cited by this paper
• Relation between the Inhibition of Aggregation and the Concentration of cAMP in Human and Rat Platelets

  1976cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper
• Stimulation of human platelet adenylate cyclase by prostaglandin D2.

  1974cited by this paper
• A simple, sensitive method for the assay of adenyl cyclase.

  1968cited by this paper
• Drug interactions

  1967cited by this paper
• The aggregation of blood platelets

  1963cited by this paper

• Antithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction

  2026cites this paper
• Prostanoid receptors in GtoPdb v.2025.3

  2025cites this paper
• Gestational diabetes mellitus is associated with in vivo platelet activation and platelet hyperreactivity.

  2024cites this paper
• Novel approaches to antiplatelet therapy.

  2022cites this paper
• Prostanoid receptors in GtoPdb v.2021.2

  2021cites this paper
• Prostaglandins prevent acetaminophen induced embryo toxicity in zebrafish (Danio rerio).

  2020cites this paper
• Biased signalling in platelet G-protein-coupled receptors.

  2020cites this paper
• Effect of Prostanoids on Human Platelet Function: An Overview

  2020cites this paper
• Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Duchenne muscular dystrophy: Focus on arachidonic acid metabolites.

  2019cites this paper
• Advances in Antiplatelet Agents

  2017cites this paper
• Genome-wide haplotype-based association analysis of major depressive disorder in Generation Scotland and UK Biobank

  2016cites this paper
• Platelet Function Tests

  2016cites this paper
• Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.

  2015cites this paper
• Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

  2015cites this paper
• An integrated approach to the design of thromboxane A2 receptor antagonists

  2014cites this paper
• Thromboxane A2 Receptor

  2012cites this paper
• Prostaglandin H synthase catalyzes the oxidation of 4-chlorobiphenyl metabolites, and the in vivo effects on prostaglandin production

  2011cites this paper
• Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake.

  2011cites this paper
• Antiplatelet therapies for the treatment of cardiovascular disease

  2010cites this paper
• Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.

  2010cites this paper
• Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families

  2009cites this paper
• Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo

  2009cites this paper
• Increased Gs signalling in platelets and impaired collagen activation, due to a defect in the dystrophin gene, result in increased blood loss during spinal surgery.

  2008cites this paper
• Platelets release active matrix metalloproteinase‐2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin

  2007cites this paper
• CHAPTER 31 – Thromboxane Generation

  2007cites this paper
• From the design to the clinical application of thromboxane modulators.

  2006cites this paper
• Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.

  2006cites this paper
• Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice

  2005cites this paper
• Direct and irreversible inhibition of cyclooxygenase-1 ( COX-1 ) by nitroaspirin ( NCX 4016 )

  2005cites this paper
• Thromboxane Receptor Blockers

  2005cites this paper
• The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies

  2005cites this paper
• Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016)

  2005cites this paper
• Randomized Trial of Ridogrel , a Combined Thromboxane A 2 Synthase Inhibitor and Thromboxane A 2 / Prostaglandin Endoperoxide Receptor Antagonist , Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction

  2005cites this paper
• In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

  2004cites this paper
• In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist

  2004cites this paper
• New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.

  2004cites this paper
• “In vitro” and “ex vivo” effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets

  2004cites this paper
• New approaches for antithrombotic antiplatelet therapies.

  2004cites this paper
• In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

  2004cites this paper
• New developments on thromboxane modulators.

  2004cites this paper
• Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.

  2003cites this paper
• Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus.

  2003cites this paper
• Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2.

  2003cites this paper
• NCX4016: a novel antithrombotic agent.

  2003cites this paper
• Drugs in development.

  2002cites this paper
• Prostaglandin Endoperoxides and Thromboxane A2 Activate the same Receptor Isoforms in Human Platelets

  2002cites this paper
• Recent developments of thromboxane modulators

  2001cites this paper
• Inhibitors of platelet signal transduction as anti-aggregatory drugs

  2001cites this paper
• Aspirin in Patients with Coronary Artery Disease: Is it Simply Irresistible?

  2001cites this paper
• NQ-Y15 inhibits the calcium mobilization by elevation of cyclic AMP in rat platelets.

  2001cites this paper
• Genetic Variation of the Extra-large Stimulatory G Protein α-Subunit Leads to Gs Hyperfunction in Platelets and Is a Risk Factor for Bleeding

  2001cites this paper
• Antiplatelet and anticoagulant effects of "HN-11 500," a selective thromboxane receptor antagonist.

  2001cites this paper
• Platelets Release their Lysosomal Content In Vivo in Humans upon Activation

  2000cites this paper
• Involvement of platelets in experimental mouse trypanosomiasis: evidence of mouse platelet cytotoxicity against Trypanosoma equiperdum.

  2000cites this paper
• New trends in thromboxane and prostacyclin modulators.

  2000cites this paper
• Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.

  1999cites this paper
• Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole.

  1999cites this paper
• Inhibitory Effect of Piracetam on Platelet-rich Thrombus Formation in an Animal Model

  1998cites this paper
• Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.

  1998cites this paper
• Antiplatelet agents isolated from medicinal plants.

  1998cites this paper
• Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.

  1997cites this paper
• Platelet Activation Markers in Patients with Peripheral Arterial Disease

  1997cites this paper
• Inhibition rather than Enhancement of Hemostatic System Activation during Initiation of Oral Anticoagulant Treatment

  1997cites this paper
• Therapeutic Aspects of Platelet Pharmacology

  1997cites this paper
• Textbook of Coronary Thrombosis and Thrombolysis

  1997cites this paper
• ZD9583, an Orally Effective Thromboxane A2 Synthase Inhibitor and Receptor Antagonist with a Sustained Duration of Action in Rat and Dog

  1997cites this paper
• Acute effects of thromboxane dual blocker (KDI-792) on different portions of lower limb blood flow--a study using Doppler ultrasonography and laser Doppler flowmetry in type 2 diabetic patients.

  1997cites this paper
• Comparison of the Effects of Different Low Molecular Weight Heparins on the Hemostatic System Activation In Vivo in Man

  1997cites this paper
• Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes.

  1997cites this paper
• New Antithrombotic Drugs for Coronary Artery Disease

  1996cites this paper
• On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.

  1996cites this paper
• Platelet and endothelial cell function in patients with insulin-dependent diabetes mellitus with excellent, good, or poor metabolic control.

  1996cites this paper
• Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.

  1996cites this paper
• New antithrombotic drugs for systemic and local delivery for coronary artery disease.

  1995cites this paper
• Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.

  1995cites this paper
• A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.

  1995cites this paper
• Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.

  1995cites this paper
• Novel Antithrombotic Drugs in Development

  1995cites this paper
• Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood.

  1995cites this paper
• Thromboxane A2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells.

  1995cites this paper
• Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).

  1995cites this paper
• New developments in antiplatelet and antithrombotic therapy.

  1995cites this paper
• New pyridazinone derivatives as inhibitors of platelet aggregation

  1995cites this paper
• 2‐Heteroaryl 2‐Substituted Phenylketone Derivatives and Their Inhibitory Activity on Platelet Aggregation

  1995cites this paper
• Role of nitric oxide in hemostatic system activation in vivo in humans.

  1995cites this paper
• Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor

  1994cites this paper
• Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.

  1994cites this paper
• A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.

  1994cites this paper
• Thia-prostanoid analogs with combined thromboxane receptor antagonist/thromboxane synthase inhibitor activities. Synthesis and pharmacological evaluation

  1994cites this paper
• Randomized Trial of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor and Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction: The Ridogrel Versus Aspirin Patency Trial (RAPT)

  1994cites this paper
• EXPERIMENTAL DISEASE Detection of Activated Feline Platelets in Platelet-rich Plasma by Use of Fluorescein-labeled Antibodies and Flow Cytometry

  1994cites this paper
• Formation of PGD(2) Contributes to the Anti-aggregatory Efficacy of ZD1542, a Thromboxane A(2) Synthase Inhibitor and TP Receptor Antagonist, in Human Whole Blood.

  1994cites this paper
• Effects of a Low Molecular Weight Heparin (Fragmin®) and of Unfractionated Heparin on Coagulation Activation at the Site of Plug Formation In Vivo

  1994cites this paper
• 5 – Inhibitors of Fatty Acid-Derived Mediators

  1994cites this paper
• Ex Vivo Inhibition of Platelet Aggregation in Patients with Severe Limb Arteriopathy Treated with BAY U3405, a Specific IX A2 Receptor Antagonist

  1994cites this paper
• Detection of Activated Feline Platelets in Platelet-rich Plasma by Use of Fluorescein-labeled Antibodies and Flow Cytometry

  1994cites this paper
• Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.

  1994cites this paper
• Advances in pharmacology and therapy of nephritides.

  1994cites this paper
• 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.

  1994cites this paper